Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AZD-8421 by AstraZeneca for Metastatic Ovarian Cancer: Likelihood of Approval
AZD-8421 is under clinical development by AstraZeneca and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData, Phase...
Data Insights
AZD-8421 by AstraZeneca for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
AZD-8421 is under clinical development by AstraZeneca and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...